Particle Therapy 2017

H-N Phase II/III Randomized Trial (MDACC) Oropharyngeal Cancer - IMPT vs IMRT

IMPT (70 Gy(RBE)) Chemotherapy (locally advanced disease)

R A N D O M I Z A T I O N

Eligibility

Follow-up

No Surgery

Stage III-IV oropharyngeal cancer

1)

Treatment 33 days

Recovery 10 wks

PROs

Restaging

Squamous cell

2)

Q3 mo

carcinoma

ECOG<2

Surgery

Follow-up

3) 4)

PROs

Target volume

IMRT (70 Gy) Chemotherapy (locally advanced disease)

delineation

PROs Q3 mo

Primary endpoint: CTC-AE G3+ toxicity at 90 days – 2 years

Frank – PI Trial Activated – Sept 2013

Courtesy Steve Frank